» Articles » PMID: 37701135

Non-alcoholic Fatty Liver Disease: Immunological Mechanisms and Current Treatments

Overview
Specialty Gastroenterology
Date 2023 Sep 13
PMID 37701135
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of NAFLD is widely recognised, the precise triggers for disease progression are still to be fully elucidated. Furthermore, the propagation to cirrhosis is poorly understood. Whilst some progress in terms of treatment options have been explored, an incomplete understanding of the hepatic cellular and molecular alterations limits their clinical utility. We have therefore reviewed some of the key pathways responsible for the pathogenesis of NAFLD such as innate and adaptative immunity, lipotoxicity and fibrogenesis, and highlighted current trials and treatment options for NAFLD patients.

Citing Articles

Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet.

Arivazhagan L, Delbare S, Wilson R, Manigrasso M, Zhou B, Ruiz H JHEP Rep. 2025; 7(2):101222.

PMID: 39911943 PMC: 11795143. DOI: 10.1016/j.jhepr.2024.101222.


Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Rubino J, Ring N, Patel K, Xia X, MacKenzie T, diFlorio-Alexander R Biomedicines. 2025; 13(1.

PMID: 39857664 PMC: 11760488. DOI: 10.3390/biomedicines13010080.


Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017-2018.

He M, Du X, Liu Y BMC Gastroenterol. 2025; 25(1):20.

PMID: 39833665 PMC: 11744826. DOI: 10.1186/s12876-025-03612-9.


Immunology and treatments of fatty liver disease.

Tang S, Wu S, Zhang W, Ma L, Zuo L, Wang H Arch Toxicol. 2024; 99(1):127-152.

PMID: 39692857 DOI: 10.1007/s00204-024-03920-1.


Efect of N-acetylcysteine on HepG2 cells which were induced into fatty liver cells.

Gholamrezapour M, Taghizadeh Ghavamabadi R, Taghavi M, Dehghani Soltani S, Shabanizadeh A, Vazirinejad R J Mol Histol. 2024; 56(1):27.

PMID: 39630170 DOI: 10.1007/s10735-024-10313-2.


References
1.
Srinivas A, Suresh D, Santhekadur P, Suvarna D, Kumar D . Extracellular Vesicles as Inflammatory Drivers in NAFLD. Front Immunol. 2021; 11:627424. PMC: 7884478. DOI: 10.3389/fimmu.2020.627424. View

2.
Mirea A, Toonen E, van den Munckhof I, Munsterman I, Tjwa E, Jaeger M . Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Mol Med. 2019; 25(1):16. PMC: 6498541. DOI: 10.1186/s10020-019-0084-3. View

3.
Liu X, Pan Q, Zhang R, Shen F, Yan S, Sun C . Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016; 22(44):9844-9852. PMC: 5124990. DOI: 10.3748/wjg.v22.i44.9844. View

4.
Ortiz-Lopez N, Fuenzalida C, Dufeu M, Pinto-Leon A, Escobar A, Poniachik J . The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol. 2022; 13:954869. PMC: 9589255. DOI: 10.3389/fimmu.2022.954869. View

5.
Jeong S, Shin W, Oh Y . Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Front Endocrinol (Lausanne). 2023; 14:1150360. PMC: 10069645. DOI: 10.3389/fendo.2023.1150360. View